COMPASS FINANCIAL MANAGEMENT LLC’s Axsome Therapeutics AXSM Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$127K	Buy	+590	New	+$128K	0.02%	513

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's AXSM Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 590 shares worth $127K. The stake represents 0.02% of the portfolio and ranks #513 among its holdings.

325 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

COMPASS FINANCIAL MANAGEMENT LLC held 590 shares of Axsome Therapeutics worth $127K as of Q2 2026.
Axsome Therapeutics was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
Axsome Therapeutics made up 0.02% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #513 holding.
325 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.